Dr. David R. Benavides, M.D., PH.D.
Neurology (Neurology Physician)
110 S Paca St, 3rd Floor
Baltimore, MD 21201
Who else practices at this address →
Baltimore city includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 76
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Texas Southwestern Medical School at Dallas
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MD license D77507
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Maryland Medical Center Baltimore, MD
Medical groups
- University of Maryland Neurology Associates PA (54 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 76
- Services billed
- 146
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 34 | 24 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 27 | 13 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 26 | 11 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 18 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dalfampridine Er (dalfampridine) | 26 |
| Baclofen Other prescribers in Baltimore, MD | 18 |
| Gabapentin Other prescribers in Baltimore, MD | 18 |
| Gilenya (fingolimod hcl) | 13 |
| Fingolimod (fingolimod hcl) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $599 in total to this clinician.
| Providence Medical Technology, Inc. | $487 |
|---|---|
| Roche Products Limited | $84.84 |
| Novartis Pharmaceuticals Corporation | $26.49 |
| Food and Beverage | $599 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,458 in research payments for these studies, mostly to the institutions running them.
- Phase III study of Satralizumab in AE
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.